<DOC>
	<DOCNO>NCT01234779</DOCNO>
	<brief_summary>This randomize , double-blind , placebo- active-controlled , parallel group study evaluate safety efficacy RO4917838 ( bitopertin ) patient acute exacerbation schizophrenia . Patients randomize receive either RO4917838 10 mg RO4917838 30 mg olanzapine 15 mg placebo orally daily 4 week inpatient , 4-week follow-up period .</brief_summary>
	<brief_title>A Study RO4917838 ( Bitopertin ) Patients With Acute Exacerbation Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Adult patient , 1865 year age Diagnosis schizophrenia ( Diagnostic Statistical Manual Mental Disorders DSM IVTR ) Acute exacerbation begin within prior 8 week Female patient must surgically sterile postmenopausal , agree use effective contraception duration study Current psychiatric diagnosis schizophrenia Alcohol substance dependence within 3 month abuse within 1 month ( except nicotine ) Electroconvulsive therapy ( ECT ) within prior 6 month Previous treatment RO4917838 another GLYT inhibitor Current treatment olanzapine , previous treatment intolerability lack response Treatment longacting injectable antipsychotic within 2 dose interval Treatment &gt; 2 antipsychotic within 3 month History neuroleptic malignant syndrome Have treatmentresistant schizophrenia judge treat physician fail two trial accord criterion protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>